Email this article 
Hide
Show all
Debate
Low-dose stavudine trials: a public health priority for developing countries
Southern African Journal of HIV Medicine | Vol 13, No 1 | a154 |
DOI: https://doi.org/10.4102/sajhivmed.v13i1.154
| © 2012 W D Francois Venter, Steve Innes, Mark Cotton
| This work is licensed under CC Attribution 4.0
Submitted: 15 December 2012 | Published: 13 March 2012
Submitted: 15 December 2012 | Published: 13 March 2012
About the author(s)
W D Francois Venter, Wits Reproductive Health and HIV Institute (WRHI), Department of Medicine, University of the Witwatersrand and Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South AfricaSteve Innes, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa
Mark Cotton, Children’s Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children’s Hospital and Stellenbosch University, Western Cape, South Africa
Abstract
The debate around relooking at stavudine dosing, both in terms of the adult low-dose stavudine study and more broadly, is welcome. The study being proposed to evaluate low-dose stavudine v. tenofovir is a fairly standard placebo-controlled non-inferiority study. The study design is not controversial; however, the choice of study drug has attracted critical attention.
Keywords
No related keywords in the metadata.
Metrics
Total abstract views: 3260Total article views: 3890
Crossref Citations
1. Multistep Continuous Flow Synthesis of Stavudine
Cloudius R. Sagandira, Faith M. Akwi, Mellisa B. Sagandira, Paul Watts
The Journal of Organic Chemistry vol: 86 issue: 20 first page: 13934 year: 2021
doi: 10.1021/acs.joc.1c01013